Get the Stockscreener App
6.90
1.57%
-0.11
Tango Therapeutics Inc stock is traded at $6.90, with a volume of 1.50M.
It is down -1.57% in the last 24 hours and up +3.29% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$7.01
Open:
$7.04
24h Volume:
1.50M
Relative Volume:
0.48
Market Cap:
$767.70M
Revenue:
$42.51M
Net Income/Loss:
$-116.49M
P/E Ratio:
-6.1607
EPS:
-1.12
Net Cash Flow:
$-120.82M
1W Performance:
+1.92%
1M Performance:
+3.29%
6M Performance:
+192.37%
1Y Performance:
-37.39%
1-Day Range:
$6.80
$7.19
1-Week Range:
$6.60
$7.42
52-Week Range:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.90 | 803.30M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Live Scanner Shows Breakout on Tango Therapeutics Inc.Wall Street Watch & Verified Chart Pattern Signals - thegnnews.com
Statistical indicators supporting Tango Therapeutics Inc.’s strengthWeekly Investment Report & Free Risk Controlled Daily Trade Plans - Newser
How to track smart money flows in Tango Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Visualizing Tango Therapeutics Inc. stock with heatmapsJuly 2025 Earnings & Verified High Yield Trade Plans - Newser
Tango Therapeutics Inc. recovery potential after sell off2025 Buyback Activity & Weekly Chart Analysis and Guides - Newser
Is This a Bottoming Phase for Tango Therapeutics Inc.Earnings Growth Report & Free Safe Entry Trade Signal Reports - newsyoung.net
Advanced analytics toolkit walkthrough for Tango Therapeutics Inc.Sell Signal & Technical Analysis for Trade Confirmation - Newser
How to forecast Tango Therapeutics Inc. trends using time seriesPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser
Analyzing recovery setups for Tango Therapeutics Inc. investorsMarket Performance Recap & Risk Controlled Stock Alerts - Newser
Full technical analysis of Tango Therapeutics Inc. stockWeekly Trend Recap & Weekly High Potential Alerts - Newser
Analyzing drawdowns of Tango Therapeutics Inc. with statistical tools2025 Volatility Report & Free Expert Verified Stock Movement Alerts - Newser
Tango Therapeutics Inc. stock chart pattern explained2025 Growth vs Value & AI Enhanced Trading Signals - Newser
Applying big data sentiment scoring on Tango Therapeutics Inc.Fed Meeting & Safe Entry Zone Tips - Newser
Tango Therapeutics Inc. stock trend forecastQuarterly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Using Python tools to backtest Tango Therapeutics Inc. strategiesWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Risk vs reward if holding onto Tango Therapeutics Inc.Trade Volume Summary & Short-Term High Return Ideas - Newser
Can technical indicators confirm Tango Therapeutics Inc.’s reversal - Newser
Piper Sandler initiates Tango Therapeutics stock with Overweight rating - Investing.com
What’s next for Tango Therapeutics Inc. stock price2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - Newser
Can Tango Therapeutics Inc. stock recover from recent declineWeekly Profit Recap & Capital Efficiency Focused Ideas - Newser
Tango Therapeutics Inc. Shows Risk Reward Favoring UpsideInflation Watch & Risk Managed Trade Strategies - beatles.ru
How moving averages guide Tango Therapeutics Inc. tradingJuly 2025 Review & Entry Point Confirmation Alerts - Newser
What Fibonacci levels say about Tango Therapeutics Inc. reboundJuly 2025 Pullbacks & Weekly High Return Opportunities - Newser
What machine learning models say about Tango Therapeutics Inc.2025 Market WrapUp & Fast Momentum Stock Entry Tips - Newser
Why Tango Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Opening Moves & Expert Curated Trade Setups - Newser
Can swing trading help recover from Tango Therapeutics Inc. lossesJuly 2025 Technicals & Long-Term Safe Investment Ideas - Newser
Analyzing Tango Therapeutics Inc. with risk reward ratio charts2025 Technical Overview & Fast Entry High Yield Stock Tips - Newser
Applying Elliott Wave Theory to Tango Therapeutics Inc.July 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
Price action breakdown for Tango Therapeutics Inc.Market Risk Summary & Technical Buy Zone Confirmations - Newser
Technical Charts Suggest Momentum Shift in Tango Therapeutics Inc. - sundaytimes.kr
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tango Therapeutics Inc Stock (TNGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Douglas | General Counsel |
Feb 04 '25 |
Sale |
2.99 |
2,774 |
8,289 |
68,570 |
| Barry Douglas | General Counsel |
Feb 05 '25 |
Sale |
3.16 |
2,556 |
8,081 |
66,014 |
| Beckman Daniella | Chief Financial Officer |
Feb 04 '25 |
Sale |
2.99 |
4,284 |
12,801 |
154,232 |
| Beckman Daniella | Chief Financial Officer |
Feb 05 '25 |
Sale |
3.16 |
3,948 |
12,481 |
150,284 |
| Crystal Adam | See Remarks |
Feb 04 '25 |
Sale |
2.99 |
7,432 |
22,207 |
165,061 |
| Crystal Adam | See Remarks |
Feb 05 '25 |
Sale |
3.16 |
6,851 |
21,659 |
158,210 |
| Weber Barbara | Chief Executive Officer |
Feb 04 '25 |
Sale |
2.99 |
9,778 |
29,217 |
1,631,264 |
| Weber Barbara | Chief Executive Officer |
Feb 05 '25 |
Sale |
3.16 |
9,013 |
28,494 |
1,622,251 |
| Rothenberg Mace | Director |
Nov 18 '24 |
Buy |
3.78 |
10,000 |
37,800 |
31,250 |
| Rothenberg Mace | Director |
Nov 14 '24 |
Buy |
3.62 |
10,000 |
36,200 |
21,250 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):